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Abstract
AIM: To evaluate mucosal healing in patients with 
small bowel plus  colonic Crohn’s disease (CD) with 
a single non-invasive examination, by using PillCam 
COLON 2© (PCC2).
METHODS: Patients with non-stricturing nonpene-
trating small bowel plus  colonic CD in sustained 
corticosteroid-free remission were included. At diagnosis, 
patients had undergone ileocolonoscopy to identify 
active CD lesions, such as ulcers and erosions, and 
small bowel capsule endoscopy to assess the Lewis 
Score (LS). After ≥ 1 year of follow-up, patients 
underwent entire gastrointestinal tract evaluation 
with PCC2. The primary endpoint was assessment of 
CD mucosal healing, defined as no active colonic CD 
lesions and LS < 135.
RESULTS: Twelve patients were included (7 male; 
mean age: 32 years), and mean follow-up was 38 mo. 
The majority of patients (83.3%) received immuno-
suppressive therapy. Three patients (25%) achieved 
mucosal healing in both the small bowel and the colon, 
while disease activity was limited to either the small 
bowel or the colon in 5 patients (42%). It was possible 
to observe the entire gastrointestinal tract in 10 of the 
12 patients (83%) who underwent PCC2.
CONCLUSION: Only three patients in sustained 
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corticosteroid-free clinical remission achieved mucosal 
healing in both the small bowel and the colon, highlighting 
the limitations of clinical assessment when stratifying 
disease activity, and the need for pan-enteric endoscopy 
to guide therapeutic modification.
Key words: Crohn’s disease; Mucosal healing; Capsule 
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Core tip: Our study reports for the first time the use of 
PillCam COLON2 Capsule (PCC2) to evaluate mucosal 
healing of the entire intestinal tract in small bowel plus 
colonic Crohn’s disease. Only 25% of our patients in 
corticosteroid-free clinical remission achieved mucosal 
healing in both the small bowel and the colon, while 
in 42% there was disease activity limited to either the 
small bowel or the colon. Endoscopic evaluation of 
the entire gastrointestinal tract with PCC2 was both 
feasible and safe. Our results highlight the limitations 
of clinical assessment when stratifying disease activity 
and emphasize the need for pan-enteric endoscopy in 
order to guide therapeutic adjustment.
Boal Carvalho P, Rosa B, Dias de Castro F, Moreira MJ, Cotter J. 
PillCam COLON 2© in Crohn’s disease: A new concept of pan-
enteric mucosal healing assessment. World J Gastroenterol 2015; 
21(23): 7233-7241  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v21/i23/7233.htm  DOI: http://dx.doi.
org/10.3748/wjg.v21.i23.7233
INTRODUCTION
Crohn’s disease (CD) is a chronic inflammatory 
bowel disease whose prevalence has been rising 
over the past decades[1]. In CD, there is a transmural 
inflammatory process that may affect the entire 
gastrointestinal tract, from the mouth to the anus, and 
in half the patients there is involvement of both the 
small bowel and colon[2]. Although the terminal ileum, 
easily accessible through ileocolonoscopy, is the most 
commonly affected small bowel segment in CD (around 
80%)[2], up to half of the patients suffering from ileal 
CD have concomitant jejunal mucosal damage[3]. 
Furthermore, one third of patients present with isolated 
proximal lesions, associated with an increased risk of 
relapse and poorer disease outcomes[3], but whose 
observation has often been challenging or incomplete.
Capsule endoscopy first became available in 
2001[4], revolutionizing the investigation of small 
bowel diseases. In the most recent European Crohn’
s and Colitis Organization guidelines[2], small bowel 
capsule endoscopy (SBCE) was established as a valid 
and important diagnostic tool in the diagnosis and 
evaluation of CD. SBCE was shown to be superior to 
small bowel follow-through and computed tomography 
enterography (CT-E) in the evaluation of the small 
bowel[5]. When compared with magnetic resonance 
enterography (MRI-E), small studies showed that 
SBCE had better sensitivity for proximal small bowel 
mucosal lesions[6]. Capsule endoscopy is highly 
sensitive for superficial mucosal lesions, with a strong 
negative predictive value[7,8]. In established CD, 
capsule endoscopy may be used to evaluate the extent 
and activity of disease[3,9], often having an impact on 
therapeutic decisions[10-12].
Mucosal healing, defined as the resolution of 
active inflammatory lesions in the gut[13], is now 
recognized as a major determinant on the outcome 
of CD[13]. Ileocolonoscopy is the gold standard for 
mucosal healing evaluation, but it is an invasive 
procedure, associated with discomfort and pain 
often requiring sedation and analgesia, and reaching 
only to the terminal ileum. Procedural risks such as 
perforation are significantly increased in patients with 
severe disease[14], and such patients would benefit 
from a less invasive diagnostic procedure. Capsule 
endoscopy, particularly when coupled with scoring 
systems such as the Lewis Score (LS)[2] or the Capsule 
Endoscopy Crohn’s Disease Activity Index (CECDAI 
or Niv Score)[2], has the potential for assessing and 
quantifying mucosal healing in small bowel CD[2].
Recently, a capsule aimed at colonic observation has 
been developed[15], PillCam COLON 2© (PCC2, Given 
Imaging©), which has been primarily used for colorectal 
cancer screening in average risk populations or when 
colonoscopy is contraindicated or incomplete[16-18]. 
Some recent studies have focused on the potential 
role of colon capsule endoscopy in patients with 
ulcerative colitis[19,20] and colonic CD[21]. PCC2 allows 
for the continuous and non-invasive observation of 
the entire intestinal tract (pan-endoscopy), and new 
studies are emerging to analyze its effectiveness in 
such evaluation[22]. Although it still requires bowel 
preparation, colon capsule endoscopy does not require 
insufflation or sedation; the risks associated with the 
procedure are minimal, although capsule retention 
and potential bowel obstruction are significantly more 
frequent in patients with established CD[4,17].
We aimed to evaluate mucosal healing in patients 
with small bowel plus colonic CD on corticosteroid-free 
clinical remission, with at least 1 year of follow-up after 
diagnosis, using PCC2 for pan-endoscopy.
MATERIALS AND METHODS
This retrospective single center study, based on 
prospectively collected data, included patients with 
small bowel plus colonic CD at diagnosis, with a non-
stricturing, non-penetrating phenotype (Montreal 
Classification L3, B1[1]), who were in corticosteroid-
free remission (defined for an Harvey-Bradshaw Index 
Table 1  Inclusion and exclusion criteria
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< 5[1]), had at least 1 year of follow-up, and were 
aged > 18 years. Exclusion criteria were pregnancy, 
known intestinal obstruction or current obstructive 
symptoms, non-steroidal anti-inflammatory drug use 
in the 4 wk prior to enrolment as well as previous 
intestinal surgery. Inclusion and exclusion criteria 
are summarized in Table 1. Small bowel radiological 
imaging was not mandatory prior to inclusion in this 
study; patients with no clinical features of stricturing 
or penetrating disease and no stricture at the index 
ileocolonoscopy were allowed to undergo capsule 
endoscopy without previous small bowel imaging.
All patients underwent both SBCE (PillCam SB2, 
Given Imaging©) and ileocolonoscopy at diagnosis 
as per the department protocol. Small bowel disease 
activity was assessed using the LS. The LS is calculated 
through a specific formula using the presence of 
villous edema, ulcers and stenosis, and classifies small 
bowel inflammatory activity in 3 grades: LS < 135 
(no activity), 135 ≤ LS < 790 (mild activity) and LS 
≥ 790 (moderate to severe activity); in this study, 
patients with LS ≥ 135 were included[23,24]. Capsule 
observation was performed by 3 physicians with 
experience in capsule endoscopy, and the images were 
read at a maximum of 10 frames per second. Colonic 
lesions included were ulcers and aphthous ulcerations, 
while other lesions such as pseudopolyps, granularity 
without mucosal breaks or nodularity were considered 
non-active CD. Disease activity, measured with the 
Harvey-Bradshaw Index (HBI), therapy (salicylates, 
corticosteroids, immunomodulators and anti-tumor 
necrosis factor-α) and disease complications were 
evaluated during follow-up.
Assessment of mucosal healing was performed 
with the PCC2, using our own modified protocol from 
Herrerías-Gutiérrez et al[25] and Cotter et al[26]. Patients 
were instructed to have a low-fiber diet and ingest at 
least 10 glasses of water 2 d before the procedure; 
on the day before the procedure, a clear liquid diet 
(water, tea, transparent beverages) was prescribed, 
as well as 1 L of polyethylene glycol solution plus 500 
mL of water between 7 and 9 pm; on the day of the 
procedure, another liter of this solution plus 500 mL of 
water was ingested (between 6:30 and 8:30 am), and 
fasting was warranted afterwards. At 9 am patients 
were instructed to ingest the capsule. Prior to the 
ingestion, real-time viewing (Rapid Access Real Time; 
Given Imaging©) was initiated and the adaptive frame 
rate mode was activated to ensure visualization of the 
entire small bowel (Figure 1).
One hour later, using the real-time viewing system, 
capsule progression to the small-bowel was confirmed, 
and 10 mg of domperidone was administered if the 
capsule was still in the stomach. Thirty minutes later, 
capsule progression was assessed, and, in the case 
of delayed stomach emptying, endoscopic capsule 
placement in the small bowel was performed. When 
the small bowel was reached, a booster of 30 mL 
of sodium phosphate solution (Fleet Phospho Soda; 
Casen-Fleet Laboratories©) was administered, followed 
by ingestion of 1 L of water; 3 h later a second booster 
of sodium phosphate (15 mL) was administered (plus 
500 mL of water) if the capsule was not excreted 
by then, and after an additional 3 h, a bisacodyl 
suppository was given. In the event of an incomplete 
examination, unless the patient reported capsule 
excretion, an abdominal X-ray was performed after a 
period of 15 d or if obstructive symptoms developed.
Capsule observation was performed by a physician 
with experience in capsule endoscopy, blinded to both 
the initial endoscopic procedures and current therapy. 
The images were read at a maximum of 10 frames per 
second, using both cameras sequentially for colonic 
evaluation and a single camera for the remainder 
of the gastrointestinal tract. Small bowel, colon 
(segmented as follows: cecum, ascending, transverse, 
descending/sigmoid colon, and rectum) and upper 
gastrointestinal CD lesions were described, and LS was 
calculated. Gastric transit time (from the first gastric 
frame to first duodenum frame), small bowel transit 
time (from the first duodenum frame to first cecum 
frame) and colonic transit time (from the first cecum 
frame to last rectal frame) were noted in minutes. 
In the case of incomplete examination (capsule not 
excreted during battery time) a colon transit time was 
defined from the first cecal frame to the last registered 
colon frame. Small bowel and colon preparation quality 
was classified with a graded scale ranging from 1 to 
4, where 1 was excellent (no more than small bits of 
residue), 2 was good (some residue, not enough to 
interfere with the examination), 3 was fair (enough 
residue to preclude a completely reliable examination) 
and 4 was poor (large amount of residue)[25].
A blood panel was performed both at diagnosis 
and on the day of the pan-endoscopy (complete 
blood count, C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), ferritin and albumin). 
Anemia was defined as hemoglobin < 12 g/dL in 
women and < 13 g/dL in men; iron deficiency was 
defined as ferritin levels < 100 μg/L, leukocytosis was 
defined as a white blood count > 11.000/μL, elevated 
CRP was defined as levels ≥ 3 mg/L, elevated ESR 
Inclusion and exclusion criteria
Inclusion criteria (all of the following)
      Small bowel plus colonic Crohn's disease
      Non-stricturing, non-penetrating phenotype
      Corticosteroid-free remission (Harvey-Bradshaw Index < 5)
      Follow-up ≥ 1 yr
      Age ≥ 18 yr
Exclusion criteria (any of the following)
      Pregnancy
      Intestinal obstruction/obstructive symptoms
      Intestinal surgery
      Non-steroidal anti-inflammatory drug use within 4 wk of enrolment 
Boal Carvalho P et al . Mucosal healing in CD with PCC2
Table 2  Hematological results at diagnosis and follow-up 
(mean ± SD)
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was defined as > 20 mm/h, and hypoalbuminemia 
was defined as levels < 3.5 mg/dL, according to our 
laboratory reference range.
The Ethics Committee of the Centro Hospitalar do 
Alto Ave, E.P.E approved this study. All patients gave 
their written informed consent before enrolment. 
Data were analyzed anonymously to preserve patient 
confidentiality. Statistical analysis of frequencies was 
performed using the SPSS v.21.0 (IBM Corp., Armonk, 
NY, United States).
RESULTS
Twelve patients were included at baseline, and all 
completed the study protocol. Five patients were 
female (41.7%); the mean age was 32 years (range: 
18-50 years), and mean follow-up was 40 mo (14-65 
mo). Mean HBI at diagnosis was 9.64 (range: 6-17). 
Two patients reported regular tobacco consumption 
(10-20 cigarettes/d), 3 were ex-smokers and 7 were 
non-smokers.
On baseline SBCE, mean LS was 1022 ± 810 
(range: 168-2980), and was highest in the third 
tercile (mean: 994 ± 838; range: 112-2980); mild 
inflammatory activity (135 ≤ LS < 790) was present 
in 5 patients and moderated to severe inflammatory 
activity (LS ≥ 790) was found in the other 7 patients. 
No small bowel stenoses were observed. On baseline 
ileocolonoscopy, 8 patients (66.7%) presented with 
a segmental pattern of colonic lesions, the majority 
in the right colon (n = 5); in 4 patients, there was 
extensive mucosal damage throughout the entire 
colon. The laboratory results at diagnosis and at the 
time of the PCC2 are summarized in Table 2.
The majority of patients (83.3%) were medicated 
with immunosuppressive therapy. Two patients were 
treated with combination immunomodulation therapy 
(adalimumab plus azathioprine), 8 with azathioprine in 
monotherapy and 2 with oral mesalazine
Mean gastric transit time was 45 ± 38 min (range: 
3-90 min); domperidone administration was warranted 
in 4 patients, and endoscopic placement was needed 
in 3 of them, with no subsequent complications. Mean 
small bowel transit time was 90 ± 37 min (range: 
21-162 min). Mean colon transit time was 321 ± 308 
min (range: 20-936). Two pan-endoscopy procedures 
were incomplete (17%), the splenic flexure being 
reached in both of them. In these patients, the colon 
transit time was 895 and 936 min (total battery time 
9 am 10 am
3 h after 1st 
NaP booster
3 h after 2nd 
NaP booster
Real-time viewing
Stomach Small bowel
Domperidone 
10 mg
30 mL NaP 
+ 
1 L H2O 15 mL NaP 
+ 
0.5 L H2O
Bisacodyl 
suppository 
(10 mg)
Real-time after 
30 min Small bowel
PCC2 
ingestion
Stomach 
Endoscopic 
placement of 
the PCC2
30 mL NaP 
+ 
1 L H2O
After the 1st NaP booster + 1 L H2O - clear liquids are allowed
After the 2nd NaP booster + 0.5 L H2O - a light meal is allowed
Figure 1  Department protocol for pan-enteric evaluation with PCC2©[40]. PCC2: Pillcam colon capsule 2©; NaP: Sodium phosphate.
Result Diagnosis Follow-up Reference
Hemoglobin (g/dL) 13.2 ± 2.8 14.2 ± 1.4 12.0-18.0
Leucocytes (103/μL) 10.100 ± 3.200   7.800 ± 2.800 4.8-10.8
Platelets (103/μL)   363 ± 194   265 ± 124 150-350
Erythrocyte sedimentation 
rate (mm/h)
  28.6 ± 23.8 12.3 ± 8.3 0-14
C-reactive protein (mg/L)   42.6 ± 36.4   17.2 ± 17.0 < 2.9
Ferritin (ng/mL)   120 ± 112   74 ± 49 26-388
Albumin (ng/mL)   4.1 ± 0.6   3.9 ± 0.3 3.1-17.5
Boal Carvalho P et al . Mucosal healing in CD with PCC2
Table 3  Patient characteristics, Crohn's disease therapy and endoscopic findings
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for the PillCam COLON 2© is 1020 min).
Small bowel cleanliness was excellent in 5 (42%) 
patients, good in 6 (50%), and fair in 1 (8%), while 
the colonic preparation was excellent in 2 patients 
(17%), good in 6 (50%) patients, fair in 2 (17%), and 
poor in 2 (17%).
PCC2 findings in the small bowel were as follows: 
complete mucosal healing of the small bowel (LS < 
135) was achieved in 4 patients (33%), 3 of them 
under azathioprine monotherapy, while the other 
patient was treated with mesalazine; one patient (8%) 
with previous moderate to severe inflammatory activity 
treated with anti-tumor necrosis-α plus azathioprine 
presented with mild inflammatory activity, and 
moderate to severe inflammatory activity was found 
in the remaining patients (n = 7, 58%). In 4 patients 
(33%), a single stenosis was found on the small bowel, 
all on the third tercile, and was ulcerated in 2 of them; 
the stenoses were traversed in all patients, causing no 
obstructive symptoms.
Mean LS was 1551 ± 1999 (range: 0-5392), and 
was highest in the third tercile (1126 ± 1213; range: 
0-3040). Colonic lesions were found in half the patients 
(n = 6); 2 patients presented with ulcers throughout 
the entire colon, while segmental inflammatory activity 
was found in the remaining 4. Six patients (50%) 
achieved complete mucosal healing of the colon; in 3, 
there was concomitant small bowel mucosal healing. 
Patient characteristics, CD therapy, and endoscopic 
findings are summarized in Table 3.
DISCUSSION
In our study of patients in corticosteroid-free clinical 
remission, we found significant inflammatory activity 
in 9/12 (75%), and crucially, in 5 patients (42%), 
disease with previous both small bowel and colonic 
involvement was limited to one of those segments on 
follow-up, highlighting the limitations of clinical disease 
assessment when stratifying disease activity, and the 
need for therapeutic modification.
Moreover, in 3 out of 6 of the patients with 
normal colonic mucosa, there was involvement of the 
proximal small bowel, an independent risk factor for 
disease relapse[3]. Conversely, 2 patients, in whom no 
significant inflammatory activity was found in the small 
bowel (LS < 135), were shown to have multiple ulcers 
in the colonic mucosa. Finally, moderate to severe 
activity in the small bowel, as well as colon disease, 
was confirmed in a third of our patients.
Adequate small bowel preparation was achieved in 
all 12 patients, and in only 2 was colonic preparation 
poor. These results are comparable to those reported 
in the literature for both the small bowel and the 
colon[4], but warrant consideration of whether it is 
possible to further optimize colon preparation.
Although this was a single center retrospective 
study with a small number of patients, it was based 
on prospectively collected data, with strict inclusion 
criteria, and it focused on a very relevant hot topic 
in CD that has not previously been investigated - the 
Patient Age 
(yr)
Sex Follow-up 
(mo)
Therapy SBCE LS Index colonoscopy colon 
findings
PCC2 LS PCC2 colon findings
1 21 Male 48 Azathioprine 2.5 mg/kg 
per day
2980 Extensive ulcers and erythema 
in entire colon
1068 Extensive ulcers in entire colon
2 21 Female 63 Azathioprine 2.5 mg/kg 
per day
Adalimumab 40 mg eow
1440 Extensive ulcers and erythema 
in entire colon
2336 No lesions
3 26 Male 57 Azathioprine 2.5 mg/kg 
per day
Adalimumab 40 mg eow
1350 Aphtoid ulcers and erythema 
in the sigmoid
  562 No lesions
4 48 Male 33 Azathioprine 2.5 mg/kg 
per day
1240 Aphtoid ulcers and erythema 
in the cecum
5392 Extensive ulcers in the ascending 
and transverse colon
5 24 Male 39 Mesalazine 3 g/d 1104 Aphtoid ulcers in the cecum 1518 Aphtoid ulcers in the cecum
6 27 Female 14 Azathioprine 2.5 mg/kg 
per day
  900 Extensive ulcers and erythema 
proximal to the splenic flexure
      0 Ulcers in the transverse colon
7 18 Male 14 Azathioprine 2.5 mg/kg 
per day
1690 Extensive ulcers and erythema 
in entire colon
2336 Ulcers in the cecum, ascending, 
transverse and descending colon
8 35 Female 22 Azathioprine 2.5 mg/kg 
per day
  314 Aphtoid ulcers and erythema 
in the cecum
5392 No lesions
9 32 Male 22 Mesalazine 3 g/d   458 Extensive ulcers and erythema 
in entire colon
      0 No lesions
10 46 Female 49 Azathioprine 2.5 mg/kg 
per day
  393 Extensive ulcers and erythema 
proximal to the splenic flexure
      0 No lesions
11 50 Female 65 Azathioprine 2.5 mg/kg 
per day
  225 Ulcers in the sigmoid       8 Ulcerative lesions in the splenic 
flexure;
12 39 Male 62 Mesalazine 3 g/d   168 Aphtoid ulcers in the cecum 
and ascending colon
      0 No lesions
SBCE: Small bowel capsule endoscopy; LS: Lewis Score; eow: Every other week; PCC2: PillCam COLON 2©.
Boal Carvalho P et al . Mucosal healing in CD with PCC2
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simultaneous evaluation of post-treatment mucosal 
healing in both the small bowel and colon with a single 
non-invasive endoscopic examination. 
In CD, symptom remission has not been shown to 
alter the natural course of the disease[13], particularly 
regarding complication and surgical rates[27], arguably 
because the correlation between clinical and inflam-
matory activities is poor[28]. In the era of biologic 
therapy, a new concept, mucosal healing, has arisen. 
In contrast to clinical symptoms, mucosal healing has 
been associated with significantly reduced rates of 
surgery[29] and hospitalization[30] as well as with the 
achievement of long term steroid-free remission[31].
Optimal assessment of mucosal healing is still 
debated. Ileocolonoscopy is currently the gold standard 
for evaluating mucosal healing, but it is an invasive 
procedure and restricted to the colon and distal 
ileum[32]. Several surrogate markers for mucosal 
healing exist, but none are without limitations. Fecal 
markers, such as calprotectin, have shown promising 
discriminating power to predict disease relapse[33], but 
the results regarding ileal disease are unremarkable[34]. 
Cross-sectional imaging, particularly CT-E and MR-E, 
allows the evaluation of the small bowel and colonic 
mucosa, as well as deep-tissue assessment, and 
has shown good correlation with both clinical and 
endoscopic activity[13]. However, CT poses a cumulative 
radiation risk, and MR-E is expensive and not widely 
available in clinical practice. SBCE has shown superior 
diagnostic accuracy to cross-sectional imaging in small 
bowel CD[6,35,36], particularly in detecting proximal and 
superficial lesions[5,6], and was recently reported to be 
safe in established small bowel CD, even in patients 
with previously known stenotic lesions[32], but does not 
allow for colon observation.
The colon capsule was recently developed for 
colon observation, particularly in patients who refuse 
colonoscopy or in whom such a procedure is not 
possible[17]. Although it still requires colon preparation, 
there is no need for insufflation or sedation, and the 
risks associated with the procedure are minimal[4,17]. 
Colon capsule endoscopy to detect mucosal inflam-
mation in the colon was previously described in 
ulcerative colitis patients[19,20], and was recently shown 
to have a good correlation with colonoscopy when 
evaluating colon mucosal damage in patients with 
colonic CD[21]. The use of colon capsule endoscopy for 
observation of the whole intestinal tract was previously 
reported by Remes-Troche et al[22] and by Negreanu 
et al[37]. In both studies, PCC2 allowed for a thorough 
examination of both the small bowel and the colon, 
with very good tolerability and no complications
No stenosis was encountered during SBCE at 
diagnosis, but single small bowel stenoses were 
found in 4 patients on PCC2. These patients reported 
no obstructive symptoms either before or during 
the procedure, and such results are consistent with 
those reported by Niv et al[32], where 6 patients with 
ulcerated small bowel stenoses underwent repeated 
SBCE with no case of retention or complications. 
The cecum was reached in all patients, allowing 
for the crucially important observation of the terminal 
ileum, ileocecal valve, and the cecum. Despite 
the optimized protocol and prolonged battery life 
(maximum 17 h), the procedure was incomplete in 2 
patients. 
Gastric transit time was per protocol always under 
90 min. In contrast to other colon capsule preparation 
regimens[22,25], we used real-time viewing to adjust 
drug administration, allowing for criterious use of 
prokinetic drugs only in patients with delayed gastric 
emptying, as well as for determination of the ideal 
timing for sodium phosphate booster delivery.
Small bowel transit time was under 3 h in all 
patients. Despite some evidence that the small bowel 
transit time correlates with diagnostic yield in SBCE[38], 
the possibility that the shortening of small bowel 
transit time might reduce the diagnostic yield with 
PCC2 would probably not be an issue as its dynamic 
frame rate allows for the capture of up to 35 frames 
per second in accelerated movement.
Colon transit times averaged 320 min, and we 
encountered 2 incomplete studies, whose colon transit 
times were 895 and 936 min - a completion rate of 
83.3%. No colon lesions were found in these patients 
despite the splenic flexure being reached in both of 
them. Both patients reported the excretion of the 
capsule on the following day with no complications. 
The completion rate for colon capsule endoscopy 
is reported to range between 76%-100%[18,19,22,39], 
comparable to our own findings (83%). Finally, we had 
no technical failures.
Our study has some limitations: it was an 
exploratory single center study, which included a 
limited number of patients due to strict inclusion 
criteria, particularly the requirement of both ileoco-
lonoscopy and SBCE at diagnosis, a minimum 
follow-up of 1 year after the initiation of CD therapy, 
and corticosteroid-free clinical remission, prior to 
mucosal healing assessment with PCC2. Secondly, 
as the objective of the study was to demonstrate the 
feasibility of PCC2 for the evaluation of small bowel 
and colonic mucosal healing, no control group or 
gold standard was employed. Prospective multicenter 
studies would enable the inclusion of a significantly 
larger number of patients to validate our preliminary 
results, with the primary outcome of assessment 
of complete mucosal healing in both small bowel 
and colonic mucosa; ideally, new studies should use 
new or adapted scoring systems that could measure 
inflammatory activity both in the small bowel and the 
colon, as this novel concept becomes widespread in 
the investigation of this pan-enteric disease, based 
on a compromise of high diagnostic accuracy, less 
invasiveness, and convenience for patients. Further 
investigations should be able to evaluate whether 
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complete (absence of endoscopically visible lesions) 
vs partial (improvement with lower inflammatory 
activity scores) mucosal healing in each and/or 
both “segments” (small bowel and/or colon) have 
a significant prognostic value, by following patients 
to assess for endpoints such as the rate of clinical 
relapses, hospitalization, or surgery. Although the 
possibility of full assessment of mucosal healing 
during the course of CD by means of a single non-
invasive procedure seems a very attractive concept, 
there is currently not enough evidence that such a 
strategy could positively impact on disease outcomes; 
moreover, key practical drawbacks such as the high 
cost of each examination, the time required to read 
the videos, and the relatively scarce availability 
of adequately trained medical staff to read PCC2 
videos, are some of the issues that currently limit its 
widespread generalizability for use in clinical practice, 
beyond those patients unwilling or unable to undergo 
conventional ileocolonoscopy.
In conclusion, the PillCam COLON 2© allows for a 
new concept of non-invasive, safe, and well tolerated 
examination of the entire gastrointestinal tract. 
Additionally, in a population currently in corticosteroid-
free clinical remission, we found significant inflam-
matory activity in all but 3 patients (25%); of relevance, 
5 patients (42%) with previous activity in both the 
small bowel and colon presented with disease limited 
to one of these, reinforcing the importance of entire 
gut visualization before any management decisions 
regarding CD patients. In the future, this procedure 
may be used to evaluate mucosal healing in the small 
bowel, particularly with proximal distribution, and 
colonic CD.
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